Mycophenolate Mofetil Hydrochloride

Phase 1Small molecule

Mycophenolate Mofetil Hydrochloride is one of 5 small molecule programs targeting Lung Transplant Recipient. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung Transplant RecipientRecruiting

Lung Transplant RecipientPhase 1

Recruiting

Competition

Competitive Landscape

4 competitors in Lung Transplant Recipient

#DrugCompanyPhaseTrials

Valcyte

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

2 2

Rayos

RRoxane Laboratories

Phase 1

1 3

Kineret

SSwedish Orphan Biovitrum

Phase 1

1 4

Imuran

LLegacy Health System

Phase 1

1 5

Mycophenolate Mofetil Hydrochloride

VVanderbilt University Medical Center

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Lung Transplant Recipient

NCT04469842

Clinical

Trials by Indication[1]

Lung Transplant Recipient1 trial

Early Use of Long-acting Tacrolimus in Lung Transplant Recipients

Recruiting·VVanderbilt University Medical Center·Phase 1·NCT04469842·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mycophenolate Mofetil Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mycophenolate Mofetil Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mycophenolate Mofetil Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vanderbilt University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: VVanderbilt University Medical Center

Mycophenolate Mofetil Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Lung Transplant Recipient1 trial

References

Drug Info

Quick Facts

Related News